canertinib has been researched along with metoprolol in 1 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (metoprolol) | Trials (metoprolol) | Recent Studies (post-2010) (metoprolol) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 5,821 | 1,743 | 1,304 |
| Protein | Taxonomy | canertinib (IC50) | metoprolol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 2.573 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.176 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 4.87 | |
| Cytochrome P450 2J2 | Homo sapiens (human) | 4.87 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, OH; Denny, WA; Elliott, WL; Greis, KD; Lipka, E; Loo, JA; Rewcastle, GW; Reyner, EL; Showalter, HD; Smaill, JB; Vincent, PW | 1 |
1 other study(ies) available for canertinib and metoprolol
| Article | Year |
|---|---|
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
Topics: Acrylamides; Animals; Antineoplastic Agents; Biological Transport; Caco-2 Cells; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Humans; Mice; Mice, Nude; Morpholines; Neoplasm Transplantation; Phosphorylation; Pyrimidines; Quinazolines; Receptor, ErbB-2; Solubility; Spectrometry, Mass, Electrospray Ionization; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |